Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity

Jun 25, 2021, 01:26 PM

Headliner
Share
Subscribe
Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the Wegovy approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version. 
Share
Subscribe
Next
Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Top episodes
Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Tirzepatide for Weight Loss and Lowering HbA1c with Juan Frias, MD
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Key Updates in ADA Standards of Care—2024
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives